Title: Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data
Authors: Temmerman, Frederik ×
Gevers, T
Ho, T A
Vanslembrouck, Ragna
Coudyzer, Walter
van Pelt, Jos
Bammens, Bert
Pirson, Y
Drenth, J P
Nevens, Frederik #
Issue Date: Aug-2013
Publisher: Blackwell Science
Series Title: Alimentary Pharmacology & Therapeutics vol:38 issue:4 pages:397-406
Article number: 10.1111/apt.12384
Abstract: Long-acting lanreotide (LAN) 120 mg every 4 weeks reduces liver volume (LV) in patients with polycystic liver diseases (PCLD). Animal studies demonstrated that the inhibition of hepatic and renal cystogenesis is dose dependent.
ISSN: 0269-2813
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hepatology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science